Cytori Therapeutics
University of California Loses Rights to '231 Patent Licensed to Cytori; Ruling Unrelated to Celution System Family of Products
Published in Surgery Litigation and Law Weekly, July 4th, 2008
The '231 patent covers isolated adipose-derived stem cells and does not affect Cytori's commercialization of the Celution(R) System or the Company's product pipeline. However, Cytori believes that the court's decision is incorrect and that the University of California may elect to appeal the ruling.
Cytori was recently granted a foundational patent on its Celution(R) System device technology for processing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- Arthritis
A Perfect Storm Threatens Patient Access to Specialty Medical Care - Life Sciences
New life sciences study findings reported from Duke University - Obesity
Thousands Gather for the Walk from Obesity - Walk on the Capitol in Washington, DC, to Raise Awareness of Obesity - Stem Cell Research
Court Determines that University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent - Abdominal Aortic Aneurysm
Researchers from University of York discuss findings in abdominal aortic aneurysm - Abdominal Hysterectomy
Reports from E.G. Elvan and co-researchers add new data to research in abdominal hysterectomy - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
